Rasuvo and Regorafenib

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Methotrexate may cause liver problems, and using it with other medications that can also affect the liver such as regorafenib may increase that risk. In addition, regorafenib may increase the blood levels and effects of methotrexate. Avoid or limit the use of alcohol while being treated with these medications and call your doctor immediately if you experience fever, chills, joint pain or swelling, unusual bleeding or bruising, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, abdominal pain, dark urine, pale stools, and/or yellowing of the skin or eyes, as these may be signs and symptoms of liver damage. More frequent monitoring may be required by your doctor to safely use both medications. Talk to your doctor or pharmacist if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

GENERALLY AVOID: Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Methotrexate, especially at higher doses or with prolonged treatment, has been associated with hepatotoxicity including acute hepatitis, chronic fibrosis, necrosis, cirrhosis, and liver enzyme elevations.

MANAGEMENT: The use of methotrexate with other potentially hepatotoxic agents should be avoided whenever possible. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, pale stools, and jaundice. Baseline and regular monitoring of hepatic function is recommended.

MONITOR: Coadministration with regorafenib may increase the plasma concentrations of drugs that are substrates of the breast cancer resistance protein (BCRP) transporter. The proposed mechanism is decreased clearance due to BCRP-inhibition by regorafenib and its active metabolites, M-2 and M-5.

MANAGEMENT: Caution is recommended when regorafenib is used in combination with BCRP inhibitors such as methotrexate. Monitoring for signs and symptoms of increased exposure to the BCRP substrate should be considered whenever regorafenib is added to or withdrawn from therapy.

Rasuvo

Generic Name: methotrexate

Brand name: Methotrexate Sodium, Preservative Free, Otrexup, Rasuvo, Rheumatrex Dose Pack, Trexall, Xatmep

Synonyms: Rasuvo (injection), Rasuvo Injection

What is Rasuvo?

Regorafenib

Generic Name: regorafenib

Brand name: Stivarga

Synonyms: n.a.

What is Regorafenib?